HC Wainwright started coverage on shares of Urovant Sciences (NASDAQ:UROV) in a report issued on Monday, MarketBeat.com reports. The firm issued a buy rating and a $28.00 price target on the stock.
Separately, Zacks Investment Research upgraded shares of Urovant Sciences from a hold rating to a buy rating and set a $4.75 price target for the company in a research report on Tuesday, December 25th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company presently has an average rating of Buy and a consensus target price of $19.55.
NASDAQ UROV opened at $13.60 on Monday. Urovant Sciences has a 1-year low of $4.05 and a 1-year high of $14.32.
Urovant Sciences (NASDAQ:UROV) last released its quarterly earnings results on Wednesday, February 13th. The company reported ($0.87) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.09) by $0.22. On average, equities analysts expect that Urovant Sciences will post -4.21 EPS for the current fiscal year.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Asymmetry Capital Management L.P. bought a new position in Urovant Sciences in the third quarter valued at approximately $1,902,000. BlackRock Inc. bought a new position in Urovant Sciences in the third quarter valued at approximately $4,574,000. FMR LLC bought a new position in Urovant Sciences in the third quarter valued at approximately $14,400,000. Dean Capital Investments Management LLC bought a new position in Urovant Sciences in the third quarter valued at approximately $618,000. Finally, Monashee Investment Management LLC bought a new position in Urovant Sciences in the third quarter valued at approximately $630,000. Institutional investors own 21.84% of the company’s stock.
Urovant Sciences Company Profile
Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions. It is developing vibegron, an oral, once-daily, small molecule beta-3 agonist that is in Phase III trials for the treatment of overactive bladder (OAB) and OAB in men with benign prostatic hyperplasia; and in Phase IIa clinical trials for irritable bowel syndrome-associated pain.
Read More: What are catch-up contributions?
Receive News & Ratings for Urovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.